Could Ocugen $OCGN be the next Covid-mutation play?

Ocugen has inked a partnership with India’s vaccine manufacturer Bharat Biotech to distribute its Covaxin vaccinations in the United States, of which revenue, it shall earn a 45% royalty.

How is Covaxin different from all the other vaccines in the US?

Enter Covid mutations - the theory that covid-mutations may render existing vaccinations obsolete to an enhanced and more effective virus have been gernering a lot of media attention oflate.

Covaxin plays an important role here because it is (through certain clinical trials), assumed to be one of the few vaccines to show a high defence to current and future mutations of the virus.

Here over the next week, possibly Monday. interim Phase 3 II data will potentially be released for Covaxin and an EUA (Emergency Use Authorization) application will shortly follow for the USA from OCGN. ( Major Catalyst )

If you take a look at when Phase 3 Interim II results came out for Pfizer’s vaccine they were only about a month apart.

Pfizer’s Vaccine, Interim Phase 3 I: Nov 9, 2020 Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study | pfpfizeruscom

Pfizer’s Vaccine, Interim Phase 3 II: Dec 10, 2020 Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine | pfpfizeruscom

Sources:

Covid Mutations already: Coronavirus Mutations and Variants: What Does It Mean? | SRHD

Covaxin is different: How Bharat Biotech’s Covaxin Vaccine Works - The New York Times

Business Journal Article on CEO & EUA, April 1, 2020: https://www.bizjournals.com/philadelphia/news/2021/04/01/ocugen-bharat-biotech-covaxin-covid-vaccine-fda.html

This investment thesis is for educational purposes only and is not investment advice. I am not an investment advisor. Your capital is at risk when you invest.